Leading brokerages remain optimistic on a basket of stocks across healthcare, real estate, manufacturing, and pharmaceuticals, citing solid earnings visibility and sector tailwinds. has a Buy rating from Goldman Sachs with a target of ₹1,325, implying 26 percent upside. Motilal Oswal sees 32 percent potential in . Elara Capital is positive on , while Citi expects the highest upside, 43 percent, in .